|

Apatinib Mesylate Clinical Trials

9 actively recruiting trials

Also known as: apatinib

Pipeline

Phase 2: 3Phase 3: 3Phase 1/2: 1

Top Sponsors

Xiangya Hospital of Central South University1
The First Affiliated Hospital with Nanjing Medical University1
The First Affiliated Hospital of Xiamen University1
The First Affiliated Hospital of Bengbu Medical University1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1

Indications

Cancer9
Breast Cancer3
Liver Disease1
Advanced Triple-negative Breast Cancer1
HRD-positive/HER2-negative Advanced Breast Cancer1

Other9 trials

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Phase 2

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 2

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Phase 2

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Phase 1/2

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

N/A

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

N/A

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Phase 3

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.